 early phase II study new derivative camptothecin treatment leukemia lymphoma early phase II study new camptothecin analog inhibitor topoisomerase patients refractory leukemia lymphoma different treatment schedules multiinstitutional cooperative study therapy complete remissions CRs partial remissions PRs assessable non-Hodgkin lymphoma NHL patients PR Hodgkin disease HD CR PR acute lymphoblastic leukemia ALL PR acute myelogenous leukemia AML patients Single infusion weeks response leukemia lymphoma patients Sixty-minute infusions days weeks days CRs PRs patients malignant lymphoma Sixty-minute infusions day days weeks CR PRs patients acute leukemia response acute leukemia patient treatment schedule effective refractory leukemia lymphoma cases relapsed cases relapsed refractory cases Major side effects leukopenia gastrointestinal GI effective refractory leukemia lymphoma clinical study novel antitumor activity mode drug cross-resistance available antitumor drugs